Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults and adolescents with obesity by delaying gastric emptying, suppressing appetite via central satiety pathways, and stimulating glucose-dependent insulin secretion.
GLP-1 and GIP medications (like semaglutide and tirzepatide) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. They work by slowing digestion and reducing hunger signals in the brain. Treatment involves weekly or daily injections with gradual dose increases to minimize stomach upset. These drugs are most effective when combined with a calorie-controlled diet and regular physical activity.
GLP-1 receptor agonists are a class of agents that exhibit incretin effects. They facilitate weight loss by promoting satiety and delaying gastric emptying... GLP-1 acts on the CNS satiety centre, leading to decreased appetite.
Why this rating
Based on multiple Phase 3 randomized controlled trials (STEP 1-5, SURPASS) cited in the review.
Source
GLP-1 and GIP analogues in the treatment of obesity
Agata Jasińska-Balwierz et al. · Pediatria i Medycyna Rodzinna · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →